• Researchers Accidentally Discover Genetic Signature for Early Detection of Sepsis in Newborns

    Dec 05 | Diagnostics World | Researchers from Simon Fraser University in Burnaby, Canada, and the University of British Columbia in Vancouver, Canada, have discovered a genetic signature in newborn infants that can predict neonatal sepsis before symptoms show. Neonatal sepsis is difficult to diagnose because of the nonspecific clinical signs that are often considered typical behavior issues in newborns, such as difficulty feeding and irritability. Therefore, most infants are not diagnosed until they start developing or have acquired the disease. More

  • Noninvasive Malaria Test Looks for Parasites in Circulating Blood

    Dec 03 | Diagnostics World | Most people in the United States have gotten no closer to malaria than the evening news, making the devasting nature of the infection in sub-Saharan Africa hard to fathom. Possibly once or more a day, people are being bitten by pathogen-carrying mosquitoes that cause untold hours of missed work and school and ultimately claim the lives of over half a million people—most of them young children. More

  • Follow the Money: Alimetry’s Wearable Gut Health Device, PrognomiQ Launches IVD, More

    Nov 26 | Diagnostics World | Alimetry plans to commercialize its wearable gut health monitoring device; PrognomiQ launches in vitro diagnostic; and more. More

  • NOWDiagnostics OTC Syphilis Test Now Available, Detecting Alzheimer’s Earliest Stages, More

    Nov 25 | Diagnostics World | NOWDiagnostics announced that its First To Know Syphilis Test, a key tool in syphilis prevention, is available for purchase nationwide; Veravas announced the results of an analytical verification study of its VeraBIND Tau assay, a next-generation test being co-developed with Phanes Biotech for the detection of Alzheimer’s disease at its earliest, most treatable stages; and more. More

  • Illumina Announces Update to TruSight Oncology Portfolio

    Nov 21 | Diagnostics World | Illumina announced an expansion of its TruSight Oncology portfolio this week at the annual meeting of the Association of Molecular Pathology (AMP) in Vancouver, British Columbia, with TruSight Oncology 500 v2 planned for global release in mid-2025. More

  • Urine Liquid Biopsy Promises Easy Cancer Detection with miRNA, ML

    Nov 19 | Diagnostics World | A team of researchers from Institute of Science Tokyo, Japan, are using nanowires with machine learning analysis to detect cancer-associated miRNAs in urine. Their research findings were published last month online in Analytical Chemistry. More

  • How to Advance Placental Pathology

    Nov 15 | Diagnostics World | Placental pathology has potential to reveal critical insights into pregnancy complications, yet it remains underutilized in clinical trials. By incorporating placental evaluations into clinical research, doctors could better understand and treat conditions like preeclampsia and preterm birth, which are currently diagnosed based only on clinical signs. More

  • Promising Platform for the Pre-Symptomatic Detection of Parkinson’s Disease

    Nov 13 | Diagnostics World | Researchers in Israel recently showcased a novel platform that can be used in the future for the early diagnosis of Parkinson’s disease (PD) by quantifying the distribution of alpha-synuclein (α-syn) in skin biopsies. A proof-of-concept study in humans, supported in part by the Michael J. Fox Foundation, suggests the single-molecule-level detection method might enable the disease to be detected up to 20 years before the first motor symptoms appear. More

  • Breath-Based Tools Look to Battle Deadly Infectious Diseases

    Nov 12 | Diagnostics World | Recent years have seen progress toward developing tools that are designed to analyze a human breath sample to detect, diagnose, or monitor various health issues. Some of these efforts have focused on combating deadly infectious diseases, with intentions of creating cost-effective, easy-to-use breathalyzers capable of being deployed in rural, remote, and low-resource settings. More

  • Novel DELFI Approach Could Bring Space-Age Leaps in Cancer Detection

    Nov 07 | Diagnostics World | A next-generation liquid biopsy approach combining cell-free DNA (cfDNA) “fragmentome” and protein biomarker analyses could aid in the early detection of ovarian cancer, suggests a recent study by researchers in the U.S., The Netherlands, and Denmark. The DELFI-Pro classifier was found to have a high positive predictive value, a key accuracy metric. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more